Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.81 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.63 |
| ▸ | FAAH | O00519 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453635 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8293954 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9829501 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8293340 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL18560507 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8515462 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9829505 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL15649578 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL22684646 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8293270 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530244-B2 | Cyclic polypeptides for PCSK9 inhibition | MERCK SHARP & DOHME LLC (US) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530244-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | NOD1 2513/4885SLC6A5 4813/4885FAAH 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.